TYBOURNE CAPITAL MANAGEMENT (HK) LTD
CIK
1553936
Location
HONG KONG, K3
Portfolio Value
Micro
$30,933,555
Diversification
Highly concentrated
Filing Date
Global Rank
#7,007
/ 7,976
▼ 155
Top Industry
Biotechnology
100.0%
3Y Alpha vs SPY
+21.8%
Period ended 9 months ago
Filed Nov 6, 2025 · 7mo
23 quarters · since Mar 2020
Clone Performance
Jun 2023–Jun 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
+189.7%
SPY
+76.3%
Annualised alpha
+21.8%
Max drawdown
−32.8%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
4 positions · as of Sep 30, 2025 · Δ vs Jun 30, 2025Top Position
39.1%
+9.7 pts
Top 5
100.0%
+5.0 pts
Top 10
100.0%
0.0 pts
HHI
3,333
Highly concentrated+1,107
Portfolio Trend
23 quarters · across all stocks
Sector Breakdown
As of Sep 30, 2025| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $30,933,555 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increasedNo qualifying positions this quarter.
New Positions
Positions the filer opened this quarterNo qualifying positions this quarter.
4 positions ·
$30,933,555 total
· as of Sep 30, 2025
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| TSHA |
Taysha Gene Therapies, Inc.
Healthcare
|
Reduced | 3,700,000 | $12,099,000 | 39.11% | |
| FBRX |
Forte Biosciences, Inc.
Healthcare
|
Reduced | 786,647 | $11,799,705 | 38.15% | |
| ALMS |
Alumis Inc.
Healthcare
|
Held | 1,399,250 | $5,583,007 | 18.05% | |
| ZNTL |
Zentalis Pharmaceuticals, Inc.
Healthcare
|
Reduced | 961,486 | $1,451,843 | 4.69% |